U.S. markets closed

Invitae Corporation (NVTA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
31.54+1.80 (+6.05%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close29.74
Open30.10
Bid30.65 x 1300
Ask31.50 x 800
Day's Range29.77 - 31.58
52 Week Range24.16 - 61.59
Volume4,836,992
Avg. Volume3,263,323
Market Cap6.855B
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Invitae Corporation
    MYGN: Lowering target price to $34.00MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $34.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Motley Fool

    Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought

    All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.

  • Benzinga

    Invitae Strengthens Health Data Platform With Ciitizen Acquisition

    Invitae Corp (NYSE: NVTA) has agreed to acquire consumer health technology company Ciitizen for $325 million in a bid to make it easier for patients to collect their genomic and clinical information. Ciitizen, backed by several investors, including a16z, Section 32, and Verily, is building a digital platform that will enable patients to collect, store, and share their medical records. Invitae has been expanding the genomic content of its testing platform and investing in software and data scienc

  • Barrons.com

    Biotech Is Due for a Comeback. 5 Stocks That Could Lead a Revival.

    The breakout success of Moderna and the rich premiums being paid for biotech M&A targets point to the substantial value that is hiding among the sector’s dross.